• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Gout
    6 Drugs classified under this therapeutic system

    All the Therapeutic System Drugs

    full basket chart
    Multiple ingredients

    Alkalinizing Agent. Potassium Citrate 330 mg, Sodium Citrate 300 mg.
    COAT. TABS: 180. 2 tabs. 3 x dly. 1/2 hr. aft. meals.
    Urin. alk. in pyelit., pyuria, urethrit.,
    acidosis assoc. with diabetes.

    full basket chart

    Xanthine Oxidase Inhibitor. Allopurinol 100 mg, 300 mg.
    TABS: 50 x 100mg, 20, 30 x 300mg.
    Init.: 100 mg dly. Mild: 100-200 mg dly.
    Moderat. sev.: 300-600 mg dly.
    Sev.: 700-800 mg dly. If dosage on mg/
    kg bdywght. basis is required, 2-10 mg/
    kg bdywght./d. should be used.
    Once dly. after a meal. Should the dly.
    dosage exceed 300 mg and GI intoler.
    be manifested, a divided doses regim.
    may be appropr. The dosage should be
    adjust. by monitor. serum urate
    concentr. and urin. urate/uric acid
    levels at appropr. interval. See lit.
    Ped. popul.: child. <15 yrs. : 10 to 20
    mg/kg bdywght./d. up to a max. of 400
    mg dly. See lit.
    Ren. impair. : In sev. renal impair. a
    single doses of 100 mg at long. interv.
    than one day is advised. If dialysis is
    required 2 -3 times/wk. of 300-400 mg
    immed. after each dialysis with none in
    the interim.
    Hep. impair.: Reduced doses should be
    used in pts. with hep. impair. Period.
    hep. funct. monitor. during the early
    stages of ther. See lit.
    Tmt. of high urate turnover condit.,
    Dosage of Allopurinol should be at the
    lower end of the recomm. dosage
    schedule. See lit.
    Manag. of pts. with signs & sympt. of
    prim. or second. gout (acute attacks,
    tophi, joint destruct., uric acid lithiasis
    and/or nephrop.).
    Manag.. of pts. with leukemia,
    lymphoma, & malignan. who are receiv.
    cancer ther. which causes elevat. of
    serum & urin. uric acid levels.
    Manag. of pts. with recur. calcium
    oxalate calculi whose dly. uric acid excret. exceeds 800 mg/d. in male pts. and 750
    mg/d in female pts.
    Ther. in such pts. should be careful.
    assessed init.and reassessed period.to
    determ. in each case that tmt. is benefic.
    and that the benefits outweigh the risks.
    C/I: Hypersens.

    full basket chart

    Colchicine 500 mcg.
    TABS: 30. 1 tab. 3 x dly. Limit for whole
    cure: 16 tabs.
    Acute gout, FMF.

    partial basket chart

    Uric Acid Production Inhibitor. Febuxostat 80 mg.
    F.C. TABS.: 28. 80 mg×1/d no regard to
    meals. If serum uric acid is > 6 mg/dL
    (357 μmol/L) after 2-4 wks., 120 mg
    ×1/d may be consid. Retest ser. uric
    acid after 2 wks. Gout flare prophylaxis
    of at least 6 mths. is recom.
    Tmt. of chronic hyperuricaemia in cond.
    where urate deposition has already
    occurred (include. a history, presence of,
    tophus and/or gouty arthritis).
    C/I: Hypersens.

    not in the basket chart

    Urate-Oxidase. Pegloticase 32 mg/ml.
    VIAL (Concent. for sol. for IV infus.) 1.
    Adult.: 8 mg (uricase protein) given as an IV infus. every 2 wks. See lit.
    Tmt. of chron. gout in adult pts. refractory to convent. therapy.
    C/I: Hypersens.

    partial basket chart

    Potassium Sodium Hydrogen Citrate 2.427 g (6:6:3:5).
    GRANULES: 280 g. See lit.
    To dissolve uric acid calculi in urin. tract
    and prevent further stone formation.
    C/I: Pts. on sod. free diets, renal impair.,
    infect. assoc. with phosphate
    stones, infects. caused by microorg. producing urase. See lit.

    Other therapeutic systems under Musculo-Skeletal Disorders